Nagasaka A, Hara I, Imai Y, Uchikawa T, Yamauchi K, Suzuki S, Takatsuki K, Tomita A, Niinomi M, Nakagawa H
Clin Endocrinol (Oxf). 1985 Apr;22(4):437-44. doi: 10.1111/j.1365-2265.1985.tb00142.x.
Fusaric acid, an inhibitor of dopamine beta-hydroxylase, which converts dopamine to noradrenaline, lowered the blood pressure and induced a subjective improvement in patients with phaeochromocytoma. These effects may be due either to an impairment of catecholamine biosynthesis or to a direct action on the blood vessels. The use of this drug in the treatment of patients with inoperable malignant phaeochromocytoma or neuroblastoma may improve symptoms and prolong survival.
